nach oben

Erschienen in:

Open Access 18.02.2021 | Original Article

The Ever-Increasing Array of Novel Inborn Errors of Immunity: an Interim Update by the IUIS Committee

verfasst von: Stuart G. Tangye, Waleed Al-Herz, Aziz Bousfiha, Charlotte Cunningham-Rundles, Jose Luis Franco, Steven M Holland, Christoph Klein, Tomohiro Morio, Eric Oksenhendler, Capucine Picard, Anne Puel, Jennifer Puck, Mikko R. J. Seppänen, Raz Somech, Helen C Su, Kathleen E. Sullivan, Troy R. Torgerson, Isabelle Meyts

Erschienen in: Journal of Clinical Immunology | Ausgabe 3/2021

Abstract

The most recent updated classification of inborn errors of immunity/primary immunodeficiencies, compiled by the International Union of Immunological Societies Expert Committee, was published in January 2020. Within days of completing this report, it was already out of date, evidenced by the frequent publication of genetic variants proposed to cause novel inborn errors of immunity. As the next formal report from the IUIS Expert Committee will not be published until 2022, we felt it important to provide the community with a brief update of recent contributions to the field of inborn errors of immunity. Herein, we highlight studies that have identified 26 additional monogenic gene defects that reach the threshold to represent novel causes of immune defects.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Inborn errors of immunity (IEI) are generally considered to result from monogenic germline defects that manifest as increased susceptibility to severe and/or recurrent infectious diseases, autoimmune or autoinflammatory conditions, atopic manifestations, and hematopoietic or solid tissue malignancies [1]. Over the past decade, the discovery of new IEIs has been occurring at an impressive rate. Indeed, the 2011 biennial update published by the IUIS Committee update listed 191 IEIs; this number increased to 430 in the 2019 update [2, 3]. This near-exponential increase in gene discovery is being driven by the accessibility and affordability of next-generation sequencing, and the efficient application of these technologies to elucidate the molecular etiology of unsolved cases of IEIs that are likely to result from single-gene defects [4].

Over the last 12 months, we have witnessed the ongoing rapid identification, and occasionally detailed molecular, biochemical, and cellular characterization, of genetic variants that cause, or are at least associated with, human diseases impacting host defense or immune regulation. Here, we will summarize reports on variants detected in 26 genes which we consider represent novel IEI (Table 1). Many additional genetic variants have been reported recently. However, those listed here have been adjudicated by the IUIS Committee to meet the strict criteria to be considered disease-causing [57]. These criteria include:

The patient’s candidate genotype is monogenic and must not occur in individuals without the clinical phenotype;

Experimental studies must indicate the genetic variant impairs, destroys, or alters expression or function of the gene product;

The causal relationship between the candidate genotype and the clinical phenotype must be confirmed via a relevant cellular phenotype, including—where possible—rescue of a functional defect by reconstitution with the wild-type gene, or via a relevant animal phenotype [57].

Table 1

Newly validated inborn errors of immunity

Novel gene defects underlying IEI—2020
Genetic defect	Inheritance/mechanisms	T/NK cells	B cells	Ig levels	Clinical features, cellular defects, and evidence of variant pathogenicity	Table (for classication)^{[2, 3]}	Refs
PAX1 (8 patients, 3 families; 2 papers with overlapping patients)	AR (LOF)	• T⁻B⁺NK⁺ SCID • Severe T lymphopenia, low TRECs,	• Normal	• ~ Normal IgM, low IgA, normal to ↑ IgE,	• Omenn’s-like syndrome (erythroderma, lymphocytosis, eosinophilia, ↓ proliferation to PHA, severe/recurrent infections), • No thymus, T cell deficiency not corrected by HSCT despite donor chimerism • Also: otofaciocervical syndrome type 2 (OTFCS2) Validation • Reporter assays established hypomorphic LOF of mutant alleles • Patients’ derived iPSCs differentiated to thymic epithelial cells demonstrated abnormalities in thymic epithelial progenitors, consistent with failure of HSCT to reconstitute T cells • Similar to mouse model	Table 1 Subtable 1	[5, 6]
SLP76 (1 patient)	AR (LOF)	• T cells reduced, • ↓↓ CD4+, ↑ CD8+ T cell proportions • Low naïve, ↑ T_CM CD4+ T cells; • CD8+ T cell mostly clonally expanded T_EMRA • Low TRECs • NK normal numbers	• Normal numbers but ↓ class-switched memory and transitional B cells, • ↑ naïve and immature B cells	• High IgM, low IgA	• Combined immunodeficiency, • Early-onset skin abscesses, rash recurrent infections, autoimmunity, • Neutrophil dysfunction, platelets dysfunction • ↓ T cell proliferation to PHA, anti-CD3/CD28 stimulation, partially restored by IL-2 • ↓ NK cell degranulation • ↓ Actin polymerization Validation • Generation of SLP76-deficient Jurkat T cells; expressing WT or mutant SLP76 allele, mimicking patient cellular phenotypes; • Partial rescue of some of the functional defects by expression of WT SLP76	Table 1 Subtable 1	[7]
MCM10 (1 patient)	AR (LOF)	• Mild lymphopenia • ↓ T_CM, T_EM cells • ↓↓↓ NK cells (↑ CD56^bright, nearly absent CD56^dim mature NK)	• ↓ B cells	• slightly ↓ IgG, normal IgM/A	• Severe (fatal) CMV infection • HLH-like (based on biomarkers, not clinical features • Phenocopies GINS1 and MCM4 deficiencies • ↓ NK function Validation • Detailed functional analysis of MCM10 variant in primary fibroblasts, transfectants, iPSC, and CRISPR/Cas9-gene-edited NK92 human NK cell line • assessed mutant allele on NK cell development in humanized mice reconstituted with CD34⁺ HSC generated from the patients or healthy donor IPSCs	Table 2 Subtable 2	[8]
IL6ST (gp130; 12 patients, 8 families)	AD (DN)	• Normal T cell numbers • ↑ naïve CD4 and CD8 T cell proportions • ↓ T_CM CD4+ and CD8+ T cells and T_EM CD8 T cells; • ↓ MAIT, Tfh cells, • ↑ Th2, • Low to normal NK cell counts	Normal numbers of B cells, low memory B cell proportions	• Normal/low IgG, A, • Normal IgM, • Hyper IgE. • vaccine IgG normal	• HIES – STAT3-like; • Dermatitis/eczema, eosinophilia, recurrent skin infections, pneumonia, bronchiectasis, pneumatoceles with severe secondary pulmonary aspergillosis, connective tissue defects (scoliosis, face, joints, fractures, palate, tooth retention) • Phenocopies aspects of IL6R and IL11R deficiencies (due to unresponsiveness to these cytokines) Validation • LOF and DN alleles shown by overexpression in GP130 deficient HEK293T cells; • Impaired GP130/STAT3 signaling (mostly downstream of IL-6) in patients’ fibroblasts and leukocytes	Table 2 Subtable 5	[9]
IL6ST (complete deficiency; 6 patients, 4 families)	AR (LOF)	ND (death in utero or in neonatal period occurred for most affected individuals)			• Fatal Stuve-Wiedemann-like syndrome; skeletal dysplasia, lung dysfunction, renal abnormalities, thrombocytopenia, dermatitis, eczema • Defective acute phase response • Complete unresponsiveness to IL-6 family cytokines Validation • Complete LOE (for one allele) and LOF for two alleles tested by overexpression in GP130 deficient HEK293T to all cytokines tested of the IL-6 family. • Effects of variants well-characterized, including a partial rescue of patient amniocytes	Table 2 Subtable 5	[10, 11]
FNIP1 (6 patients; 5 families)	AR (LOF)	Mild T cell lymphocytosis	B cell lymphopenia (absent/low; BM block [few immature B cells])	agamma/hypogammaglobulinemia	• Early onset recurrent infections (sinopulmonary) • Bronchiectasis • Congenital heart defects (e.g., hypertrophic cardiomyopathy) • Variable neutropenia (severe or intermittent) Crohn disease (one patient) • Developmental delay • Increased AMPK activity Validation • Almost recapitulates the mouse model [12, 13]	Table 3 Subtable 1	[14, 15]
PIK3CG (2 patients; 2 families)	AR (LOF)	• Normal CD4, • ↓ Treg, ↓ CD8	• Normal but ↓ memory B cells	• Hypogamma • Intact vaccine responses	• Cytopenia/lymphopenia, eosinophilia, lymphadenopathy, splenomegaly, • recurrent infections • HLH-like; ↑ inflammatory markers Validation • ↓ T cell proliferation, activation in vitro • Cellular defects recapitulated in PIK3CG targeted Jurkat T cell line and Pik3cg ko mice	Table 3 Subtable 2	[16, 17]
CTNNBL1 (1 patient)	AR (LOF)	↓ T cells	• Reduced memory B cells; • Impaired CSR, SHM	• Progressive severe hypogamma	CVID, autoimmune cytopenias, hypogamma, recurrent infections, hyperplastic GC’s; (mutation reduces binding of CTNNBL1 to AID, resulting in less nuclear translocation of AID) Validation • detailed functional analysis of CTNNBL1 variant in EBV B lines, and engineered RAMOS cell lines; • mutant allele reduces the binding of CTNNBL1 to AID, with impaired nuclear translocation of AID; • defective SHM rescued in mutant Ramos cells by WT CTNNBL1	Table 3 Subtable 3	[18]
TNFSF13 (APRIL; 1 patient)	AR (LOF)	• Normal T/NK cells	Normal total B cell counts, ↑ IgM+ marginal zone /↓ sw memory B cells, ↓ blood plasmablasts	• Hypogamma	CVID, chronic but mild infections Validation • LOE and LOF allele, • Functional analysis of the variant in PBMCs and overexpression; • Impaired function of iPSC-moDC in promoting B cell differentiation could be rescued with exogenous APRIL	Table 3 Subtable 3	[19]
SOCS1 (15 patients; 10 families)	AD (by haploinsufficiency)	• ↓CD4, CD8 T cells	• Predom naïve B cells • ↓ sw memory, ↑ CD21lo B	• ↓ IgM, G, A but protective specific Abs; • ANA’s, autoAbs • ↑ serum BAFF	• Recurrent bacterial infections, • Severe multisystemic autoimmunity (flared in context of infection-induced inflammation), ITP, AIHA, SLE, GN, hepatosplenomegaly, psoriasis, arthritis, thyroiditis, hepatitis • Evan’s syndrome • 1 patient developed COVID19/MIS-C • neutropenia, lymphopenia • incomplete penetrance Validation • ↑ pSTAT1, ↑ type I/II IFN signature • Reporter assays confirmed impaired inhibition of mutant SOCS • Jakinib effective in vitro and in vivo.	Table 4 Subtable 4	[20‐22]
TET2 (3 patients, 2 families)	AR (LOF)	• ↑ DN T cells • ↓ Th1, Th17, Tfh cells	• ↓ Memory B cells • Impaired B cell diff in vitro to plasma cells	• Variable (hyper−/ hypogamma, ↓ response to pneumococcal vaccine	• ALPS-like (↑ sCD25, sFasL, IL10) • Recurrent viral infections, lymphadenopathy, hepatosplenomegaly, autoimmunity (cytopenias, B cell lymphoma (EBV+ HL-like) • Failure to thrive, developmental delay • EBV viremia • DNA hypermethylation • Defective FAS-mediated apoptosis	Table 4 Subtable 7	[23]
CEBPE (3 patients, 1 family)	AR (GOF)	• Mild lymphopenia •↓ naive, ↑ T_EMRA cells	ND	ND	• Recurrent abdominal pain, aseptic fever, systemic inflammation; abscesses, ulceration, infections; mild bleeding diathesis • Autoinflammasome activation/↑ IFN gene expression (autoinflammation, immunodeficiency, neutrophil dysfunction) Validation • homozygous CEBPE variant affecting DNA binding domain, associated with autoinflammation/immunodeficiency • showed altered chromatin occupancy of mutant CEBPE, and transcriptional changes, in patient cells targeting inflammasome and IFN-related genes	Table 5 Subtable 2	[24]
TBX21 (T-bet; 1 patient)	AR (LOF)	• Normal %’s total, CD4 and CD8 T cells, naïve and memory subsets, low frequencies of NK cells • ↓ CXCR3⁺ CCR6⁻ Th1 cells, CXCR3⁺ Tfh and CXCR3⁺ Treg CD4⁺T cells • ↑ immature NK • ↓ iNKT, MAIT, Vδ2⁺ γδ T cells	• Normal	• Normal	• MSMD • ↓IFN-γ and TNF-α production by T cell subsets (γδ T cells, MAIT cells, iNKT cells, NK cells,, Vδ2⁺γδ, Vδ1⁺γδ, and CD4⁺ T cells Validation • Biochemical and molecular analysis established the impact of this variant on Tbet function; • Impaired production of IFNγ, TNFα by TBX21-mutant naïve CD4+ T cells under Th1 polarizing cultured in vitro • Tbet-dependent functions restored in patient cells and cell lines by WT TBX21	Table 6 Subtable 1	[25]
IFNG (2 patients [cousins])	AR (LOF)	• Normal frequencies of T and NK cells; • ↑ proportions of naive CD4+ and CD8+ T cells; • ↓ frequency of invariant iNKT	• Normal B cell frequencies; • ↓ memory B cells (↓ IgA⁺ / IgM⁺, ↑ IgG⁺ memory B cells)	• Normal	MSMD/BCG-osis • No IFN-γ producing cells Validation • LOE and LOF allele • Biochemical and molecular analysis established impact of this variant on IFN-γ production from patients’ cells • No IFN-γ production by T and NK cells; • Impaired IFN-γ production by patient-derived Herpesvirus saimiri–immortalized T cells restored by introduction of WT IFNG	Table 6 Subtable 1	[26]
NOS2 (1 patient)	AR	• ↓ CD4+ T cells; • ↓ NK cells (mostly all immature cells) • normal CD8+ T	↓ B cells	ND (specific Ab levels normal)	• Severe susceptibility to CMV-induced disease; fatal • Pneumocystis pneumonia secondary to CMV • Apparent intact responses to infection with other herpes viruses (EBV, VZV, HSV) Validation: • Confirmed functional defect in transfected cells; truncated NOS2 failed to induce nitrous oxide • Recapitulates susceptibility of Nos2 deficient mice to murine CMV infection [27] (these mice are also susceptible to numerous other pathogens)	Table 6 Subtable 3	[28]
SNORA31 (5 patients, unrelated)	AD	• Normal	• Normal	• Seropositive for IgG against many viruses	• Forebrain herpes simplex virus-1 (HSV-1) encephalitis Validation: susceptibility of human pluripotent stem cell (hPSC)–derived cortical neurons from patients or hPSC-derived neurons from healthy donors but engineered to express variant SNORA31 to HSV1 infection, corrected by exogenous IFN-β • Incomplete penetrance	Table 6 Subtable 4	[29]
ATG4A (1 patient)	AD	Normal	Normal	Normal	• Mollaret’s meningitis (recurrent lymphocytic meningitis) due to HSV2 • History of multiple episodes of meningitis; HSV2⁺ Validation • Impaired HSV2-induced autophagy → increased viral replication and apoptosis of patient fibroblasts • These defects were rescued by introduction of WT ATG4 or LC3B2 into patient fibroblasts	Table 6 Subtable 4	[30]
MAP1LC3B2 (1 patient)	AD	Normal	Normal	Normal		Table 6 Subtable 4	[30]
MAPK8 (3 patients, 1 family)	AD (haploinsufficiency)	• Normal total T cells, CD4⁺ and CD8⁺ T subsets, NK cells • ↓ Th17 cells	• Normal total B cells and subsets	• Normal	• Chronic mucocutaneous candidiasis (CMC) • Connective tissue disorder (similar to Ehlers-Danlos syndrome) • ↓ Th17 cells ex vivo, in vitro • ↓ Responses of fibroblasts to IL-17A, IL-17F • ↓ c-Jun/ATF-2-dependant TGF β signaling Validation • MAKP8 variant LOE in HEK293 T, heterozygous patients’ cells (↓ Th17 cells ex vivo, in vitro; ↓ fibroblast responses to IL-17A, IL-17F; ↓ TGFβ signaling) • Defective responses of fibroblasts restored by WT MAPK8	Table 6 Subtable 6	[31]
LSM11 (2 siblings, 1 family)	AR (LOF)	Not reported			• Aicardi-Goutieres syndrome (type 1 IFN-opathy)	Table 7 Subtable 1	[32]
RNU7–1 (16 patients, 11 kindreds)	AR (LOF)	Not reported			• Aicardi-Goutieres syndrome (type 1 IFN-opathy)	Table 7 Subtable 1	[32]
CDC42 (15 patients; numerous kindreds reported in 7 papers)	AD	• Normal/decreased T cell numbers, • normal %CD4/CD8 but skewed differentiation	• Normal/B-lymphopenia	• Variable (↑↓) IgM, G, A, E	• Neonatal onset: pancytopenia, fever, rash, hepatosplenomegaly, systemic inflammation, myelofibrosis/proliferation, HLH, multisystemic inflammatory disease. • ↑ serum levels of IL1, IL18, IFN-γ, ferritin, sCD25, CRP etc. • Recurrent GIT/RT infection; • Neurodevelopmental delay, FTT • Mutation affects actin function; • Treated with Anakinra/ IFN-γ mAb ↓NK function (cytox),	Table 7 Subtable 1	[33‐39]
STAT2 (GOF, 3 patients; all deceased; 2 additional deceased sibs but not genotyped; 2 unrelated families)	AR (GOF)	• Low frequency of NK, ↑ frequency of T cells (esp naïve), normal NK degranulation	• Total B cell frequencies within age-matched controls’ ranges • slight ↑ transitional and naïve B cells %‘s	• Low/normal	• Severe fatal early-onset autoinflammation (skin ulceration, fever, seizures, intracranial calcification, multiorgan dysfunction, abnormal neurodevelopment; phenocopy of USP18 deficiency) • ↑ serum IFN-α, IL6, TNFα • IFN-opathy gene signature (impaired regulation of late cellular responses to type 1 IFN), Validation • Study of the mutant STAT2 alleles in STAT2 deficient human cell line, and patient’s immortalized fibroblasts • Patient cells hyper-sensitive to IFN-α → prolonged JAK/STAT signaling/transcriptional activation • Biochemical confirmation that mutant allele is GOF in homozygous, but not heterozygous, combination • Impaired interaction of GOF STAT2 protein with USP18, a negative regulator of type 1 IFN responses	Table 7 Subtable 1	[40, 41]
RIPK1 (12 patients; 5 families, 2 papers)	AD	• Normal T and NK cell numbers • Low/normal CD4⁺ T cells • Normal/hi CD8⁺ T cells • ↑ DN T cells	• Normal B cells	ND	• Autoinflamm disorder: regular/prolonged fevers, lymphadenopathy, spleno/hepatomegaly, ulcers, arthralgia, GI features, • ↑ inflamm markers, ↑ pro-inflamm cytokines/gene signature; • Responsive to Tocilizumab (not IL1/TNF blockade)	Table 7 Subtable 2	[42, 43]
NCKAP1L (9 patients; 7 families, 3 papers)	AR (LOF)	• Normal T cell numbers • ↑T_CM, exhausted cells; • Possibly immature NK cells but intact function	• Normal B cells and naïve/memory subsets • ↑ CD21^lo cells	• Normal/ ↑ Ig levels • autoAbs	• Recurrent URTI, skin rashes/abscesses, ulcers, • Anti dsDNA Abs, SLE-like, lymphadenopathy, fever, HLH-like • FTT • Immunodeficiency coupled with atopy, lymphoproliferation, hyperinflammation ,and cytokine overproduction (↑ Th1) • ↓ T cell proliferation, cytoskeletal defects;	Table 7 Subtable 3	[44‐46]
UBA1 (25 patients)	XL (somatic LOF mutations)	• ↓ Peripheral lymphocyte counts • Loss of immature B cells, nonclassical and intermediate monocyte populations			• Late adulthood onset treatment-refractory inflammatory syndrome • Fevers, cytopenias, dysplastic bone marrow, • Neutrophilic cutaneous and pulmonary inflammation, chondritis and vasculitis • Most patients have an inflammatory syndrome (relapsing polychondritis, Sweet’s syndrome, polyarteritis nodosa, giant-cell arteritis) or a hematologic condition (MDS, multiple myeloma) • Often fatal Dysregulated proinflammatory neutrophil activation, high inflammatory markers in patients’ serum Validation: • Overexpression of mutant allele favored the production of a catalytically deficient UBA1 • Defective ubiquitylation of patients’ mutant monocytes • CRISPR-Cas9 Uba1–deficient zebrafish model recapitulates the phenotype of systemic inflammation	Table 7	[47]
Novel phenocopies of inborn errors of immunity
Disease			Mechanisms of disease pathogenesis		Associated/clinical features	Table	Refs
Severe COVID-19			• High levels of neutralizing autoAbs against type 1 IFNs (primarily IFNα, IFNω)		• Severe, life-threatening infection with SARS-CoV-2	Table 10	[48]

Abbreviations: AR, autosomal recessive; AD, autosomal dominant; AID, activation-induced cytidine deaminase; CSR, class switch recombination; SHM, somatic hypermutation; MDS, myelodysplastic syndrome; LOE, loss of expression; LOF, loss of function; GOF, gain of function; DN, dominant negative; MSMD, Mendelian susceptibility to mycobacterial disease; HLH, hemophagocytic lymphohistiocytosis; FTT, failure to thrive; hPSC, human pluripotent stem cells; iPSC, induced pluripotent stem cells; CMV, cytomegalovirus

• Not all Tables in the 2020 classifications [2, 3] are listed in the “Table” column because not all Tables are represented by the new variants detailed above

• Mutations in PAX1 previously reported to cause OTFCS2 (but CID/SCID not reported) [49]

• Variants in IL6ST have been previously listed to cause an IEI due to recessive partial LOF alleles [50]

• Dominant-negative mutations in IL6ST all target the intracellular domain of gp130, truncating the STAT3 binding sites as well as recycling motif, leading to sustained expression of a dead receptor (as opposed to recessive alleles, when detected in heterozygous carriers are benign)

• Fnip1 ko mice also previously reported [12, 13]; humans very similar

• Variants in CEBPE have been previously listed to cause an IEI due to recessive LOF alleles [51]

• Mutations in CDC42 previously identified in individuals with neurodevelopmental delay (Takenouchi-Kosaki syndrome) [52]; in these patients with autoinflammation and CDC42 mutations no such features were noted, except mild facial dysmorphism in some [33‐39]

.• Variants in STAT2 have been previously listed to cause an IEI due to recessive LOF alleles [53, 54]

• The same amino acid was found to be affected (R148Q/W) for both families affected by STAT2 GOF [53, 54]

• Variants in RIPK1 have been previously listed to cause an IEI due to recessive LOF alleles [55, 56]; the heterozygous dominant mutations in RIPK1 reported here all affect the D324 amino acid residue that is important for cleavage

We also considered (i) the numbers of individuals affected by the novel variants, (ii) sufficient justification for excluding alternative candidate gene variants identified in single cases especially in situations of consanguinity with recessive disease, (iii) the depth of the clinical descriptions of affected individuals, and (iv) the level of immune and mechanistic characterization.

Novel Causes of Inborn Errors of Immunity

Currently, inborn errors of immunity are listed in 10 tables: Immunodeficiencies affecting cellular and humoral immunity (Table I), Combined immunodeficiencies (CID) with syndromic features (Table II), Predominantly antibody deficiencies (Table III), Diseases of immune dysregulation (Table IV), Congenital defects of phagocytes (Table V), Defects in intrinsic and innate immunity (Table VI), Autoinflammatory diseases (Table VII), Complement deficiencies (Table VIII), Bone Marrow failure (Table IX), and Phenocopies of inborn errors of immunity (Table X). Several of these tables are further partitioned into various subtables (e.g., Table I is split into Subtable 1 [T⁻B⁺ Severe Combined Immune Deficiency (SCID)], Subtable 2 [T⁻B⁻ SCID] and Subtable 3 [CID, generally less profound than SCID]) [2, 3].

Recently-reported gene defects have been found for most categories of inborn errors of immunity, including novel causes of:

SCID (PAX1 [5, 6], SLP76 [7]);
CID (MCM10 [8], IL6ST [9‐11]);
Predominantly antibody deficiencies (FNIP1 [14, 15], PIK3CG [16, 17], CTNNBL1 [18], TNFSF13 [19]);
Autoinflammatory diseases (SOCS1 [20‐22], TET2 [23], CEBPE [24], CDC42 [33‐39], LSM11, RNU7–1 [32], STAT2 [40, 41], RIPK1 [42, 43], NCKAP1L [44‐46]), UBA1 (somatic mutations) [47]; and
Susceptibility to infection with specific pathogens (MAPK8 [31]; TBX21 [25], IFNG [26], NOS2 [28], SNORA31 [29], ATG4A, MAP1LC3B2 [30]) (Table 1).

Notably, several of these genes are already included in previous IUIS updates, namely IL6ST, STAT2, CEBPE, and RIPK1 [2, 3]. However, they are listed here because the variant identified is pathogenic via a distinct mechanism and/or different mode of inheritance; i.e., autosomal recessive (AR) vs autosomal dominant for IL6ST [9] or RIPK1 [42, 43], partial deficiency vs complete deficiency for IL6ST [10, 11], or AR loss of function vs AR gain of function for CEBPE [24] or STAT2 [40, 41]. Furthermore, the GOF variants reported for CEBPE appear to represent the first described germline neomorphic mutation in inborn errors of immunity where the variant allele has completely novel functions not seen for the wild type gene [24]. Thus, these findings underscore the importance of appropriately interpreting genetic variants identified by next-generation sequencing, not discarding variants of unknown significance simply because they do not match the expected zygosity or clinical phenotype of previously reported studies, and to rigorously validate the impact of novel variants on the function of the encoded protein.

Joining the Dots with Discoveries of Novel Inborn Errors of Immunity

Many known inborn errors of immunity impact a defined signaling pathway such that mutations in components of these same pathways can represent clinical phenocopies of diseases causes by distinct genetic variants (genetic heterogeneity). In other words, physiological homogeneity can be identified for many genotypes underlying a given phenotype. Classic examples of this are Mendelian susceptibility to mycobacterial disease (MSMD), which results from impaired IFNγ-mediated immunity following exposure to mycobacterial species [58], and herpes simplex virus encephalitis (HSE) resulting from impaired TLR3-mediated anti-HSV1 immunity [59, 60]. Thus, variants in genes affecting the production of IFNγ (e.g., IL12RB1, IL12RB2, IL23R, TYK2, IKBKG, SPPL2A, IRF8) or cellular responses to IFNγ (e.g., IFNGR1, IFNGR2, STAT1, JAK1) result in MSMD in otherwise healthy individuals [58]. Similarly, inactivating mutations in signaling components of the TLR3 signaling pathway (TLR3, UNC93B, TRIF, TRAF3, TBK1, IRF3) underlie HSE due to impaired type 1 IFN-mediated central nervous system (CNS) intrinsic immunity against HSV1 [59, 60].

Recent discoveries have further linked common clinical phenotypes with unique genotypes that converge in a shared pathway. Thus, the non-redundant role of IFNγ-mediated immunity in host defense against mycobacterial infection [58] has been definitively established by the identification of individuals with inactivating bi-allelic mutations in not only IFNG itself [26] but also TBX21 [25], the transcription factor that regulates expression and production of IFNγ.

Interestingly, variants in the small nucleolar RNA SNORA31 predispose affected individuals to HSE. Mechanistically, patient’s iPSC-derived cortical neurons were found to be highly susceptible to HSV-1 infection in vitro, and this could be restored by exogenous IFNβ [29, 60]. However, responses of these cells to TLR3 and IFNβ, but not HSV1, are intact, revealing that SNORA31 functions to regulate cell-intrinsic immunity to HSV-1 by a mechanism independent of TLR3 signaling [29, 60]. The discovery of individuals with SNORA31 variants will facilitate further understanding of CNS-intrinsic host defense.

The discoveries of individuals with complete gp130-deficiency due to null/nonsense bi-allelic mutations of IL6ST [11], or pathogenic dominant-negative heterozygous variants of IL6ST [9], and a phenotype of eczema, hyper-IgE, and eosinophilia, likely explain these features of autosomal dominant hyper-IgE syndrome due to STAT3 negative dominance [61] and further highlight the role of IL-6 signaling in restraining atopic and allergic responses. Furthermore, the lack of mucocutaneous candidiasis in patients with impaired signaling via receptors for IL-6 (IL6R, IL6ST mutations [9, 11, 50, 62, 63]; anti-IL-6 autoantibodies [64]), IL-23 (biallelic IL23R variants) [65] or IL-21 (biallelic IL21 or IL21R variants) [66] argues that individually these cytokines are not required for the STAT3-mediated generation of human Th17 cells and host defense against fungal infections. Rather, the combinatorial defect of impaired STAT3 signaling downstream of these receptors explains chronic mucocutaneous candidiasis in an individual with dominant-negative STAT3 mutations. These findings again reveal the capacity for inborn errors of immunity to provide convincing evidence for basic immunological concepts. Indeed, this is further exemplified by the discovery that variants of ATG4A or MAP1LC3B2 cause recurrent HSV2 infection of the CNS, thereby establishing hitherto non-redundant functions of the autophagy pathway in non-hematopoietic cell-mediated intrinsic anti-viral immune responses [30].

SARS-CoV2 and Inborn Errors of Immunity

The COVID19 pandemic of 2020 has clearly changed the world in many ways. It has also yielded opportunities to understand host requirements for immunity against SARS-CoV2 infection. A recent study of ~ 650 individuals who developed severe COVID-19 found that ~ 3.5% of patients harbored germline loss-of-function variants in genes previously found to be important for host defense against influenza or other viral infections (e.g., bi-allelic loss of function mutations of IRF7 or IFNAR1, heterozygous mutations in TLR3, TICAM1, TBK1, or IRF3) [67] due to the key role of these genes in the type 1 IFN signaling pathway [59, 68]. An accompanying study found that, strikingly, ~ 10% of patients with severe COVID-19 have high levels of neutralizing autoantibodies (autoAbs) against type 1 IFNs in their serum [48]. The impact of these autoAbs was evidenced by the inability to detect IFN in serum from these patients, and their capacity to prevent anti-viral immune responses in vitro [48] (Table 1). These studies defined a crucial and non-redundant role for type 1 IFNs in immune control of SARS-CoV2 infection, and thus prevention of severe COVID-19. Furthermore, they also established that autoAbs against type 1 IFN phenocopy an inborn error of immunity, as previously determined for autoAbs against IFNγ and susceptibility to mycobacterial disease, anti-Th17 cytokine (IL-17A, IL-17F, IL-22) autoAbs in individuals with chronic mucocutaneous candidiasis, or pyogenic infections due to anti-IL-6 autoAbs [64, 69].

Conclusions

Discoveries over the past 12 months in the field of inborn errors of immunity have further identified non-redundant functions of key genes in human immune cell development, host defense, and immune regulation. In some cases, these functions go well beyond what may have been expected or anticipated based on animal models (e.g., TBX21 [25]). They have also already highlighted the heterogenous phenotypes that can result from variants in the same gene (e.g., CDC42 [33‐39, 52]), indicated that significant diseases can arise from mono-allelic or bi-allelic loss of function (IL6ST [9], RIPK1 [42, 43]) or bi-allelic loss- or gain-of-function (CEBPE [24], STAT2 [40, 41]) variants in the same gene, or from autoAb phenocopies of monogenic lesions (e.g., COVID19 and anti-IFN Abs) [48], and identified novel somatic mutations as pathogenic causes of immune disorders (UBA1) [47]. Importantly, they have also provided opportunities for therapeutic interventions, such as JAK inhibitors to treat STAT2 gain of function [40, 41] or SOCS1 deficiency [22], IFNγ to treat mycobacterial disease [25, 26], or early IFN-β or IFN-α2a treatment of SARS-CoV2 infection in COVID-19 patients with autoantibodies against IFN-α or IFN-ω [67] or impaired type 1 IFN responses [70]. This snapshot of genetic discoveries underpinning human immune disorders further highlights the critical contributions of inborn errors of immunity to our broader understanding of basic, translational, and clinical immunology.

Declarations

Ethics Approval

This work is a review of recently-reported genetic variants that represent novel inborn errors of immunity. No human research studies were performed in order to produce this review. Thus, no approvals by appropriate institutional review boards or human research ethics committees were required to undertake the preparation of this report.

Not applicable as this is a review of recently-reported genetic variants.

The authors consent to publish the content of this review. However, as noted above, as this is a review of recently-reported genetic variants that represent novel inborn errors of immunity, we did not require consent to publish from participants.

Conflict of Interest

The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen ¹

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt testen ²

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Jetzt testen ³

Notarangelo LD, Bacchetta R, Casanova JL, Su HC. Human inborn errors of immunity: an expanding universe. Sci Immunol. 2020;5(49):eabb1662. https://doi.org/10.1126/sciimmunol.abb1662.CrossRefPubMedPubMedCentral

Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol. 2020;40(1):66–81. https://doi.org/10.1007/s10875-020-00758-x.CrossRefPubMedPubMedCentral

Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64. https://doi.org/10.1007/s10875-019-00737-x.CrossRefPubMedPubMedCentral

Meyts I, Bosch B, Bolze A, Boisson B, Itan Y, Belkadi A, et al. Exome and genome sequencing for inborn errors of immunity. J Allergy Clin Immunol. 2016;138(4):957–69. https://doi.org/10.1016/j.jaci.2016.08.003.CrossRefPubMedPubMedCentral

Yamazaki Y, Urrutia R, Franco LM, Giliani S, Zhang K, Alazami AM, et al. PAX1 is essential for development and function of the human thymus. Sci Immunol. 2020;5(44):eaax1036. https://doi.org/10.1126/sciimmunol.aax1036.CrossRefPubMedPubMedCentral

Paganini I, Sestini R, Capone GL, Putignano AL, Contini E, Giotti I, et al. A novel PAX1 null homozygous mutation in autosomal recessive otofaciocervical syndrome associated with severe combined immunodeficiency. Clin Genet. 2017;92(6):664–8. https://doi.org/10.1111/cge.13085.CrossRefPubMed

Lev A, Lee YN, Sun G, Hallumi E, Simon AJ, Zrihen KS, et al. Inherited SLP76 deficiency in humans causes severe combined immunodeficiency, neutrophil and platelet defects. J Exp Med. 2021;218(3):e20201062. https://doi.org/10.1084/jem.20201062.CrossRefPubMed

Mace EM, Paust S, Conte MI, Baxley RM, Schmit MM, Patil SL, et al. Human NK cell deficiency as a result of biallelic mutations in MCM10. J Clin Invest. 2020;130:5272–86. https://doi.org/10.1172/JCI134966.CrossRefPubMedPubMedCentral

Beziat V, Tavernier SJ, Chen YH, Ma CS, Materna M, Laurence A, et al. Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome. J Exp Med. 2020;217(6):e20191804. https://doi.org/10.1084/jem.20191804.CrossRefPubMedPubMedCentral

10.

Monies D, Abouelhoda M, Assoum M, Moghrabi N, Rafiullah R, Almontashiri N, et al. Lessons learned from large-scale, first-tier clinical exome sequencing in a highly consanguineous population. Am J Hum Genet. 2019;104(6):1182–201. https://doi.org/10.1016/j.ajhg.2019.04.011.CrossRefPubMedPubMedCentral

11.

Chen YH, Grigelioniene G, Newton PT, Gullander J, Elfving M, Hammarsjo A, et al. Absence of GP130 cytokine receptor signaling causes extended Stuve-Wiedemann syndrome. J Exp Med. 2020;217(3):e20191306. https://doi.org/10.1084/jem.20191306.CrossRefPubMedPubMedCentral

12.

Park H, Staehling K, Tsang M, Appleby MW, Brunkow ME, Margineantu D, et al. Disruption of Fnip1 reveals a metabolic checkpoint controlling B lymphocyte development. Immunity. 2012;36(5):769–81. https://doi.org/10.1016/j.immuni.2012.02.019.CrossRefPubMedPubMedCentral

13.

Siggs OM, Stockenhuber A, Deobagkar-Lele M, Bull KR, Crockford TL, Kingston BL, et al. Mutation of Fnip1 is associated with B-cell deficiency, cardiomyopathy, and elevated AMPK activity. Proc Natl Acad Sci U S A. 2016;113(26):E3706–15. https://doi.org/10.1073/pnas.1607592113.CrossRefPubMedPubMedCentral

14.

Niehues T, Ozgur TT, Bickes M, Waldmann R, Schoning J, Brasen J, et al. Mutations of the gene FNIP1 associated with a syndromic autosomal recessive immunodeficiency with cardiomyopathy and pre-excitation syndrome. Eur J Immunol. 2020;50(7):1078–80. https://doi.org/10.1002/eji.201948504.CrossRefPubMed

15.

Saettini F, Poli C, Vengoechea J, Bonanomi S, Orellana JC, Fazio G, et al. Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin interacting protein 1 deficiency. Blood. 2021;137:493–9 https://doi.org/10.1182/blood.2020006441.

16.

Takeda AJ, Maher TJ, Zhang Y, Lanahan SM, Bucklin ML, Compton SR, et al. Human PI3Kgamma deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. Nat Commun. 2019;10(1):4364. https://doi.org/10.1038/s41467-019-12311-5.CrossRefPubMedPubMedCentral

17.

Thian M, Hoeger B, Kamnev A, Poyer F, Kostel Bal S, Caldera M, et al. Germline biallelic PIK3CG mutations in a multifaceted immunodeficiency with immune dysregulation. Haematologica. 2020;105:e488. https://doi.org/10.3324/haematol.2019.231399.CrossRefPubMed

18.

Kuhny M, Forbes LR, Cakan E, Vega-Loza A, Kostiuk V, Dinesh RK, et al. Disease-associated CTNNBL1 mutation impairs somatic hypermutation by decreasing nuclear AID. J Clin Invest. 2020;130(8):4411-4422. https://doi.org/10.1172/JCI131297.CrossRefPubMedPubMedCentral

19.

Yeh TW, Okano T, Naruto T, Yamashita M, Okamura M, Tanita K, et al. APRIL-dependent life-long plasmacyte maintenance and immunoglobulin production in humans. J Allergy Clin Immunol. 2020;146:1109–1120.e4. https://doi.org/10.1016/j.jaci.2020.03.025.CrossRefPubMed

20.

Lee PY, Platt CD, Weeks S, Grace RF, Maher G, Gauthier K, et al. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J Allergy Clin Immunol. 2020;146(5):1194–1200.e1. https://doi.org/10.1016/j.jaci.2020.07.033.CrossRefPubMedPubMedCentral

21.

Thaventhiran JED, Lango Allen H, Burren OS, Rae W, Greene D, Staples E, et al. Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature. 2020;583(7814):90–5. https://doi.org/10.1038/s41586-020-2265-1.CrossRefPubMedPubMedCentral

22.

Hadjadj J, Castro CN, Tusseau M, Stolzenberg MC, Mazerolles F, Aladjidi N, et al. Early-onset autoimmunity associated with SOCS1 haploinsufficiency. Nat Commun. 2020;11(1):5341. https://doi.org/10.1038/s41467-020-18925-4.CrossRefPubMedPubMedCentral

23.

Stremenova Spegarova J, Lawless D, Mohamad SMB, Engelhardt KR, Doody G, Shrimpton J, et al. Germline TET2 loss of function causes childhood immunodeficiency and lymphoma. Blood. 2020;136(9):1055–66. https://doi.org/10.1182/blood.2020005844.CrossRefPubMed

24.

Goos H, Fogarty CL, Sahu B, Plagnol V, Rajamaki K, Nurmi K, et al. Gain-of-function CEBPE mutation causes noncanonical autoinflammatory inflammasomopathy. J Allergy Clin Immunol. 2019;144(5):1364–76. https://doi.org/10.1016/j.jaci.2019.06.003.CrossRefPubMed

25.

Yang R, Mele F, Worley L, Langlais D, Rosain J, Benhsaien I, et al. Human T-bet governs innate and innate-like adaptive IFN-gamma immunity against mycobacteria. Cell. 2020;183(7):1826–1847.e31. https://doi.org/10.1016/j.cell.2020.10.046.CrossRefPubMedPubMedCentral

26.

Kerner G, Rosain J, Guerin A, AlKhabaz A, Oleaga-Quintas C, Rapaport F, et al. Inherited human IFNgamma deficiency underlies mycobacterial disease. J Clin Invest. 2020;130(6):3158–71. https://doi.org/10.1172/JCI135460.CrossRefPubMedPubMedCentral

27.

Noda S, Tanaka K, Sawamura S, Sasaki M, Matsumoto T, Mikami K, et al. Role of nitric oxide synthase type 2 in acute infection with murine cytomegalovirus. J Immunol. 2001;166(5):3533–41. https://doi.org/10.4049/jimmunol.166.5.3533.CrossRefPubMed

28.

Drutman SB, Mansouri D, Mahdaviani SA, Neehus AL, Hum D, Bryk R, et al. Fatal Cytomegalovirus infection in an adult with inherited NOS2 deficiency. N Engl J Med. 2020;382(5):437–45. https://doi.org/10.1056/NEJMoa1910640.CrossRefPubMedPubMedCentral

29.

Lafaille FG, Harschnitz O, Lee YS, Zhang P, Hasek ML, Kerner G, et al. Human SNORA31 variations impair cortical neuron-intrinsic immunity to HSV-1 and underlie herpes simplex encephalitis. Nat Med. 2019;25(12):1873–84. https://doi.org/10.1038/s41591-019-0672-3.CrossRefPubMedPubMedCentral

30.

Hait AS, Olagnier D, Sancho-Shimizu V, Skipper KA, Helleberg M, Larsen SM, et al. Defects in LC3B2 and ATG4A underlie HSV2 meningitis and reveal a critical role for autophagy in antiviral defense in humans. Sci Immunol. 2020;5(54):eabc2691. https://doi.org/10.1126/sciimmunol.abc2691.CrossRefPubMedPubMedCentral

31.

Li J, Ritelli M, Ma CS, Rao G, Habib T, Corvilain E, et al. Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-beta. Sci Immunol. 2019;4(41):eabc2691. https://doi.org/10.1126/sciimmunol.aax7965.CrossRef

32.

Uggenti C, Lepelley A, Depp M, Badrock AP, Rodero MP, El-Daher MT, et al. cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. Nat Genet. 2020;52(12):1364–72. https://doi.org/10.1038/s41588-020-00737-3.CrossRefPubMed

33.

Verboon JM, Mahmut D, Kim AR, Nakamura M, Abdulhay NJ, Nandakumar SK, et al. Infantile myelofibrosis and myeloproliferation with CDC42 dysfunction. J Clin Immunol. 2020;40:554–66. https://doi.org/10.1007/s10875-020-00778-7.CrossRefPubMedPubMedCentral

34.

Lam MT, Coppola S, Krumbach OHF, Prencipe G, Insalaco A, Cifaldi C, et al. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J Exp Med. 2019;216(12):2778–99. https://doi.org/10.1084/jem.20190147.CrossRefPubMedPubMedCentral

35.

Gernez Y, de Jesus AA, Alsaleem H, Macaubas C, Roy A, Lovell D, et al. Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1beta inhibition. J Allergy Clin Immunol. 2019;144(4):1122–5 e6. https://doi.org/10.1016/j.jaci.2019.06.017.CrossRefPubMedPubMedCentral

36.

Bucciol G, Pillay B, Casas-Martin J, Delafontaine S, Proesmans M, Lorent N, et al. Systemic inflammation and myelofibrosis in a patient with Takenouchi-Kosaki syndrome due to CDC42 Tyr64Cys mutation. J Clin Immunol. 2020;40:567–70. https://doi.org/10.1007/s10875-020-00742-5.CrossRefPubMed

37.

Bekhouche B, Tourville A, Ravichandran Y, Tacine R, Abrami L, Dussiot M, et al. A toxic palmitoylation of Cdc42 enhances NF-kappaB signaling and drives a severe autoinflammatory syndrome. J Allergy Clin Immunol. 2020;146(5):1201–1204.e8. https://doi.org/10.1016/j.jaci.2020.03.020.CrossRefPubMed

38.

He T, Huang Y, Ling J, Yang J. A new patient with NOCARH syndrome due to CDC42 defect. J Clin Immunol. 2020;40(4):571–5. https://doi.org/10.1007/s10875-020-00786-7.CrossRefPubMed

39.

Szczawinska-Poplonyk A, Ploski R, Bernatowska E, Pac M. A novel CDC42 mutation in an 11-year old child manifesting as syndromic immunodeficiency, autoinflammation, hemophagocytic lymphohistiocytosis, and malignancy: a case report. Front Immunol. 2020;11:318. https://doi.org/10.3389/fimmu.2020.00318.CrossRefPubMedPubMedCentral

40.

Gruber C, Martin-Fernandez M, Ailal F, Qiu X, Taft J, Altman J, et al. Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy. J Exp Med. 2020;217(5):e20192319. https://doi.org/10.1084/jem.20192319.CrossRefPubMedPubMedCentral

41.

Duncan CJA, Thompson BJ, Chen R, Rice GI, Gothe F, Young DF, et al. Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2. Sci Immunol. 2019;4(42):eaav7501. https://doi.org/10.1126/sciimmunol.aav7501.CrossRefPubMedPubMedCentral

42.

Tao P, Sun J, Wu Z, Wang S, Wang J, Li W, et al. A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1. Nature. 2020;577(7788):109–14. https://doi.org/10.1038/s41586-019-1830-y.CrossRefPubMed

43.

Lalaoui N, Boyden SE, Oda H, Wood GM, Stone DL, Chau D, et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. Nature. 2020;577(7788):103–8. https://doi.org/10.1038/s41586-019-1828-5.CrossRefPubMed

44.

Cook SA, Comrie WA, Poli MC, Similuk M, Oler AJ, Faruqi AJ, et al. HEM1 deficiency disrupts mTORC2 and F-actin control in inherited immunodysregulatory disease. Science. 2020;369(6500):202–7. https://doi.org/10.1126/science.aay5663.CrossRefPubMedPubMedCentral

45.

Salzer E, Zoghi S, Kiss MG, Kage F, Rashkova C, Stahnke S, et al. The cytoskeletal regulator HEM1 governs B cell development and prevents autoimmunity. Sci Immunol. 2020;5(49):eabc3979. https://doi.org/10.1126/sciimmunol.abc3979.CrossRefPubMedPubMedCentral

46.

Castro CN, Rosenzwajg M, Carapito R, Shahrooei M, Konantz M, Khan A, et al. NCKAP1L defects lead to a novel syndrome combining immunodeficiency, lymphoproliferation, and hyperinflammation. J Exp Med. 2020;217(12):e20192275. https://doi.org/10.1084/jem.20192275.CrossRefPubMedPubMedCentral

47.

Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383:2628–38. https://doi.org/10.1056/NEJMoa2026834.CrossRefPubMedPubMedCentral

48.

Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. https://doi.org/10.1126/science.abd4585.CrossRefPubMedPubMedCentral

49.

Pohl E, Aykut A, Beleggia F, Karaca E, Durmaz B, Keupp K, et al. A hypofunctional PAX1 mutation causes autosomal recessively inherited otofaciocervical syndrome. Hum Genet. 2013;132(11):1311–20. https://doi.org/10.1007/s00439-013-1337-9.CrossRefPubMed

50.

Spencer S, Kostel Bal S, Egner W, Lango Allen H, Raza SI, Ma CA, et al. Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. J Exp Med. 2019;216(9):1986–98. https://doi.org/10.1084/jem.20190344.CrossRefPubMedPubMedCentral

51.

Gombart AF, Koeffler HP. Neutrophil specific granule deficiency and mutations in the gene encoding transcription factor C/EBP(epsilon). Curr Opin Hematol. 2002;9(1):36–42. https://doi.org/10.1097/00062752-200201000-00007.CrossRefPubMed

52.

Su HC, Orange JS. The growing spectrum of human diseases caused by inherited CDC42 mutations. J Clin Immunol. 2020;40(4):551–3. https://doi.org/10.1007/s10875-020-00785-8.CrossRefPubMedPubMedCentral

53.

Hambleton S, Goodbourn S, Young DF, Dickinson P, Mohamad SM, Valappil M, et al. STAT2 deficiency and susceptibility to viral illness in humans. Proc Natl Acad Sci U S A. 2013;110(8):3053–8. https://doi.org/10.1073/pnas.1220098110.CrossRefPubMedPubMedCentral

54.

Moens L, Van Eyck L, Jochmans D, Mitera T, Frans G, Bossuyt X, et al. A novel kindred with inherited STAT2 deficiency and severe viral illness. J Allergy Clin Immunol. 2017;139(6):1995–7 e9. https://doi.org/10.1016/j.jaci.2016.10.033.CrossRefPubMed

55.

Cuchet-Lourenco D, Eletto D, Wu C, Plagnol V, Papapietro O, Curtis J, et al. Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation. Science. 2018;361(6404):810–3. https://doi.org/10.1126/science.aar2641.CrossRefPubMedPubMedCentral

56.

Li Y, Fuhrer M, Bahrami E, Socha P, Klaudel-Dreszler M, Bouzidi A, et al. Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2019;116(3):970–5. https://doi.org/10.1073/pnas.1813582116.CrossRefPubMed

57.

Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med. 2014;211(11):2137–49. https://doi.org/10.1084/jem.20140520.CrossRefPubMedPubMedCentral

58.

Bustamante J. Mendelian susceptibility to mycobacterial disease: recent discoveries. Hum Genet. 2020;139(6–7):993–1000. https://doi.org/10.1007/s00439-020-02120-y.CrossRefPubMedPubMedCentral

59.

Moens L, Meyts I. Recent human genetic errors of innate immunity leading to increased susceptibility to infection. Curr Opin Immunol. 2020;62:79–90. https://doi.org/10.1016/j.coi.2019.12.002.CrossRefPubMed

60.

Zhang SY. Herpes simplex virus encephalitis of childhood: inborn errors of central nervous system cell-intrinsic immunity. Hum Genet. 2020;139(6–7):911–8. https://doi.org/10.1007/s00439-020-02127-5.CrossRefPubMedPubMedCentral

61.

Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity. 2012;36(4):515–28. https://doi.org/10.1016/j.immuni.2012.03.016.CrossRefPubMedPubMedCentral

62.

Shahin T, Aschenbrenner D, Cagdas D, Bal SK, Conde CD, Garncarz W, et al. Selective loss of function variants in IL6ST cause hyper-IgE syndrome with distinct impairments of T-cell phenotype and function. Haematologica. 2019;104(3):609–21. https://doi.org/10.3324/haematol.2018.194233.CrossRefPubMedPubMedCentral

63.

Nahum A, Sharfe N, Broides A, Dadi H, Naghdi Z, Mandola AB, et al. Defining the biological responses of IL-6 by the study of a novel IL-6 receptor chain immunodeficiency. J Allergy Clin Immunol. 2020;145(3):1011–5 e6. https://doi.org/10.1016/j.jaci.2019.11.015.CrossRefPubMed

64.

Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol. 2008;180(1):647–54. https://doi.org/10.4049/jimmunol.180.1.647.CrossRefPubMed

65.

Martinez-Barricarte R, Markle JG, Ma CS, Deenick EK, Ramirez-Alejo N, Mele F, et al. Human IFN-gamma immunity to mycobacteria is governed by both IL-12 and IL-23. Sci Immunol. 2018;3(30):eaau6759. https://doi.org/10.1126/sciimmunol.aau6759.CrossRefPubMed

66.

Kotlarz D, Zietara N, Milner JD, Klein C. Human IL-21 and IL-21R deficiencies: two novel entities of primary immunodeficiency. Curr Opin Pediatr. 2014;26(6):704–12. https://doi.org/10.1097/MOP.0000000000000160.CrossRefPubMed

67.

Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. https://doi.org/10.1126/science.abd4570.CrossRefPubMedPubMedCentral

68.

Zhang Q. Human genetics of life-threatening influenza pneumonitis. Hum Genet. 2020;139(6–7):941–8. https://doi.org/10.1007/s00439-019-02108-3.CrossRefPubMed

69.

Ku CL, Chi CY, von Bernuth H, Doffinger R. Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? Hum Genet. 2020;139(6–7):783–94. https://doi.org/10.1007/s00439-020-02180-0.CrossRefPubMedPubMedCentral

70.

Levy R, Bastard P, Lanternier F, Lecuit M, Zhang SY, Casanova JL. IFN-alpha2a therapy in two patients with inborn errors of TLR3 and IRF3 infected with SARS-CoV-2. J Clin Immunol. 2021;41:26–7. https://doi.org/10.1007/s10875-020-00933-0.

Titel: The Ever-Increasing Array of Novel Inborn Errors of Immunity: an Interim Update by the IUIS Committee
verfasst von: Stuart G. Tangye
Waleed Al-Herz
Aziz Bousfiha
Charlotte Cunningham-Rundles
Jose Luis Franco
Steven M Holland
Christoph Klein
Tomohiro Morio
Eric Oksenhendler
Capucine Picard
Anne Puel
Jennifer Puck
Mikko R. J. Seppänen
Raz Somech
Helen C Su
Kathleen E. Sullivan
Troy R. Torgerson
Isabelle Meyts
Publikationsdatum: 18.02.2021
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 3/2021
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-021-00980-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The Ever-Increasing Array of Novel Inborn Errors of Immunity: an Interim Update by the IUIS Committee

Abstract

Publisher’s Note

Introduction

Novel Causes of Inborn Errors of Immunity

Joining the Dots with Discoveries of Novel Inborn Errors of Immunity

SARS-CoV2 and Inborn Errors of Immunity

Conclusions

Declarations

Ethics Approval

Conflict of Interest

Publisher’s Note

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Innere Medizin

e.Med Allgemeinmedizin

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Publisher’s Note

Introduction

Novel Causes of Inborn Errors of Immunity

Joining the Dots with Discoveries of Novel Inborn Errors of Immunity

SARS-CoV2 and Inborn Errors of Immunity

Conclusions

Declarations

Ethics Approval

Consent to Participate

Consent for Publication

Conflict of Interest

Publisher’s Note

Unsere Produktempfehlungen

e.Med Interdisziplinär

e.Med Innere Medizin

e.Med Allgemeinmedizin

Weitere Artikel der Ausgabe 3/2021

Characterization of Infants with Idiopathic Transient and Persistent T Cell Lymphopenia Identified by Newborn Screening—a Single-Center Experience in New York State

Chronic Disseminated Gonococcal Infection in a Japanese Man with Novel C5 Gene Mutation

Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia

Use of Complementary and Alternative Medicine in Patients with Primary Immunodeficiency: a Multicentric Analysis of 101 Patients

Novel IL36RN Mutation Identified in Pediatric-Onset Generalized Pustular Psoriasis Causes IL36 Antagonist Degradation

Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin